For the quarter ending 2025-09-30, ELVN made $30,442K in revenue. -$19,750K in net income. Net profit margin of -64.88%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 18,225 | 21,491 | ||
| General and administrative | 6,871 | 7,093 | ||
| Total operating expenses | 25,096 | 28,584 | ||
| Loss from operations | -25,096 | -28,584 | ||
| Interest income | 4,948 | 3,251 | ||
| Change in fair value of contingent value right liability | 0 | 0 | ||
| Income tax expense | 0 | 0 | ||
| Other expense | 0 | -2 | ||
| Total other income (expense), net | 4,948 | 3,249 | ||
| Net loss | -20,148 | -25,335 | ||
| Net unrealized gains on marketable securities | 398 | -161 | ||
| Comprehensive loss | -19,750 | -25,496 | ||
| Net loss per share, basic | -0.32 | -0.49 | ||
| Net loss per share, diluted | -0.32 | -0.49 | ||
| Weighted average number of shares outstanding, basic | 62,093,795 | 52,105,052 | ||
| Weighted-average shares outstanding, diluted | 62,093,795 | 52,105,052 | ||
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)